News Channels

26 Jun 2020 Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
26 Jun 2020 AiViva Biopharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
26 Jun 2020 Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers
26 Jun 2020 Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases
25 Jun 2020 Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study
25 Jun 2020 Acceleron Presents Topline Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension
25 Jun 2020 uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
25 Jun 2020 Breztri Aerosphere significantly reduced rate of moderate or severe COPD exacerbations in Phase III ETHOS trial
25 Jun 2020 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
25 Jun 2020 Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session
25 Jun 2020 Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine
24 Jun 2020 Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers
24 Jun 2020 Yumanity Therapeutics Announces Strategic Research Collaboration and License Agreement with Merck Focused on Accelerating the Development of New Treatments for Neurodegenerative Diseases
24 Jun 2020 Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers
24 Jun 2020 ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
24 Jun 2020 Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults
24 Jun 2020 La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
24 Jun 2020 Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients
24 Jun 2020 IM Therapeutics Announces First Patient Dosed in Phase 1 Study of Its Lead Drug IMT-002 for Type 1 Diabetes
24 Jun 2020 Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up